ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Newron Pharmaceuticals Spa.

Newron Pharmaceuticals Spa. (NP5)

9.60
-0.34
( -3.42% )
Updated: 04:14:47
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
9.60
Bid
9.50
Offer
9.60
Volume
8,775
9.52 Day's Range 10.08
6.65 52 Week Range 13.50
Market Cap
Previous Close
9.94
Open
10.08
Last Trade
124
@
9.6
Last Trade Time
04:14:47
Financial Volume
-
VWAP
-
Average Volume (3m)
7,969
Shares Outstanding
17,845,345
Dividend Yield
-
PE Ratio
-10.30
Earnings Per Share (EPS)
-0.91
Revenue
9.06M
Net Profit
-16.22M

About Newron Pharmaceuticals Spa.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Milan, Lombardy, Ita
Founded
-
Newron Pharmaceuticals Spa. is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker NP5. The last closing price for Newron Pharmaceuticals was 9.94 €. Over the last year, Newron Pharmaceuticals shares have traded in a share price range of 6.65 € to 13.50 €.

Newron Pharmaceuticals currently has 17,845,345 shares in issue. The market capitalisation of Newron Pharmaceuticals is 177.38 € million. Newron Pharmaceuticals has a price to earnings ratio (PE ratio) of -10.30.

NP5 Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.11.052631578959.510.5399999.02118039.68369287DE
40.728.108108108118.8810.5399998.3883519.35945942DE
12-0.03-0.3115264797519.6313.57.2279698.99439239DE
261.2414.83253588528.3613.57.2261328.73370874DE
52-2-17.241379310311.613.56.6596859.10343613DE
1568.074529.0956749671.52613.51.1364017.3761957DE
2603.4556.09756097566.1513.51.1345496.71453043DE

NP5 - Frequently Asked Questions (FAQ)

What is the current Newron Pharmaceuticals share price?
The current share price of Newron Pharmaceuticals is 9.60 €
How many Newron Pharmaceuticals shares are in issue?
Newron Pharmaceuticals has 17,845,345 shares in issue
What is the market cap of Newron Pharmaceuticals?
The market capitalisation of Newron Pharmaceuticals is EUR 177.38M
What is the 1 year trading range for Newron Pharmaceuticals share price?
Newron Pharmaceuticals has traded in the range of 6.65 € to 13.50 € during the past year
What is the PE ratio of Newron Pharmaceuticals?
The price to earnings ratio of Newron Pharmaceuticals is -10.3
What is the cash to sales ratio of Newron Pharmaceuticals?
The cash to sales ratio of Newron Pharmaceuticals is 18.44
What is the reporting currency for Newron Pharmaceuticals?
Newron Pharmaceuticals reports financial results in EUR
What is the latest annual turnover for Newron Pharmaceuticals?
The latest annual turnover of Newron Pharmaceuticals is EUR 9.06M
What is the latest annual profit for Newron Pharmaceuticals?
The latest annual profit of Newron Pharmaceuticals is EUR -16.22M
What is the registered address of Newron Pharmaceuticals?
The registered address for Newron Pharmaceuticals is VIA ANTONIO MEUCCI 3, BRESSO, MILAN, LOMBARDY, 20091
What is the Newron Pharmaceuticals website address?
The website address for Newron Pharmaceuticals is www.newron.com
Which industry sector does Newron Pharmaceuticals operate in?
Newron Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
6XVThredUp Inc
1.87 €
(47.24%)
4k
E3O1Nexoptic Technology Corp
0.024 €
(41.18%)
676
7XSPSPI Energy Co Ltd
1.14 €
(34.12%)
10.39k
A4YACCENTRO Real Estate AG
0.266 €
(29.13%)
24.02k
36WWeimob Inc
0.302 €
(29.06%)
846
1UR1Bee Vectoring Technologies International Inc
0.003 €
(-45.45%)
6.8k
H5EHelma Eigenheimbau Ag
0.06 €
(-36.58%)
15
WWTWater Ways Technologies Inc
0.003 €
(-33.33%)
28.97k
CNWCodon AG
0.0075 €
(-31.82%)
3.83k
4XHFreeport Resources Inc
0.0135 €
(-28.95%)
10k
D7GNel ASA
0.1918 €
(-1.89%)
17.84M
PF8European Lithium Limited
0.0342 €
(14.77%)
4.39M
DI6Distribuidora Internacional De Alimentacion SA
0.0172 €
(-0.58%)
3.09M
RQ0DWave Quantum Inc
4.005 €
(6.97%)
2.74M
QJ4Auric Minerals Corp
1.203 €
(14.57%)
2.71M

Discussion

View Full Feed
stock_observer_77 stock_observer_77 5 minutes ago
Watching but afraid to buy.....it may hit weekly MA8
subslover subslover 5 minutes ago
Wow, I forgot all about this pretty baby! Thank you for waking me up. Papi always takes care of his friends.🤩😇
MTNB
QueenVic QueenVic 6 minutes ago
Yup.I hear ya!
As I say about them ppl ...

Ignorance is a bliss.
And they have 🐷 💩 narratives and theories.
getmoreshares getmoreshares 6 minutes ago
some slapping!
ZHUD
m0n m0n 6 minutes ago
Due to the halt LoL.  Blame Canada $TWOH
TWOH
netmoney1999 netmoney1999 6 minutes ago
LOL so this thing is deep down in trips at a 52wk+ low and you're still pumping. Oh, and its back to .0004
💩💩💩
EPAZ
Horseman Country Horseman Country 6 minutes ago
https://investorshub.advfn.com/uimage/uploads/2025/1/14/mmbclIMG_1058.jpeg
FNMA
Mufaso Mufaso 6 minutes ago
It's not just what Brian Lian said, but also what Big Pharma CEOs are saying. For instance, PFE's CEO Albert Bourla said on yesterday's JPM webcast that it's "a little late" to be developing an injected GLP-1-based therapy. PFE wants oral molecules and/or non-GLP-1 mechanisms. (There was no update o
GLP JPM PFE
IB_ IB_ 6 minutes ago
After years and YEARS of "topping off" and "buying the dips" what will your 36,000 shares of ELTP be worth when Elite is doing $200 + million in fiscal 2026, 👸 ?????????????????????

IB_🤴
ELTP
Monksdream Monksdream 7 minutes ago
Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company, which engages in developing neuroscientific solutions for mental illnesses and neurological disorders. It offers Brain Network Analytics (BNA) platform, a software as a medical solution for the diagnostic and treatment
AIFF
m0n m0n 7 minutes ago
the day $TWOH was halted on the CSE the volume was 19milky.  The second highest volume on that day was over half the volume of $TWOH.

It's stupid a CSE halt affects the USA side of things.  Either way, on the 10th business day, FINRA can lift the halt here which will be Thursday but f
TWOH
ma snart ma snart 7 minutes ago
You know Hunter that you and I own more shares than has been traded on a daily basis for months now, this is gonna slowly make us rich and its so funny that people on the sidelines are going to wait till we are much higher to buy in so they will be "certain" in their investments,,, we will be laughi
SINC
Horseman Country Horseman Country 7 minutes ago
https://investorshub.advfn.com/uimage/uploads/2025/1/14/mmbclIMG_1058.jpeg
FNMA
DeafTrader2 DeafTrader2 8 minutes ago
This R/S will not harm investors ...
LODE
MRc2 MRc2 8 minutes ago
lol.....eom
ILLR
3331 3331 8 minutes ago
You always say read this or that, but never provide a specific answer. Obviously, you can't. DO BETTER!
BIEL
Ftor Ftor 8 minutes ago
what time is Bill Acman's presentation on Jan 16th? And how to watch it?

thanks in advance
FNMA
waterchaser waterchaser 8 minutes ago
Mining is one of the biggest scams on the OTC.

MJ is a close second... so I'm guessing HIRU will become a weed stock at some point.
HIRU
12x 12x 8 minutes ago
The omission in the PR is glaring, and it’s hard not to wonder if the company is intentionally withholding information from investors.

That’s the most disappointing part. This is an investment conference—an ideal platform to highlight key achievements. With the MAA accepted and a peer
AVXL
Jetmek_03052 Jetmek_03052 8 minutes ago
Very interested.

I'm always interested in exposing a company that regularly promises its investors success but never delivers.

DBMM is a PRIME example of such a company.

The next Q coming out will simply be more proof that DBMM is a failure at its busines
DBMM
DeafTrader2 DeafTrader2 8 minutes ago
To achieve these objectives, we require an increase in the authorized shares of Comstock Inc. To that end, we are convening a special meeting on February 14, 2025 , where shareholders will be asked to vote on a proposal that effectively increases our authorized shares – including a reverse stock
LODE

Your Recent History

Delayed Upgrade Clock